Fevipiprant

Fevipiprant (INN; code name QAW039) is a drug that is currently under investigation for its potential to treat asthma. It is being developed by Novartis and was announced in a press release in 2015. Fevipiprant is a prostaglandin D2 receptor 2 antagonist which has been shown to reduce asthmatic inflammation in the airways.

Mechanism of Action

Fevipiprant works by blocking the prostaglandin D2 receptor 2 (DP2). DP2 is a receptor found on the surface of certain cells in the body, including those in the lungs. When prostaglandin D2 (a type of fat molecule) binds to these receptors, it can cause inflammation and constriction of the airways. By blocking these receptors, Fevipiprant can help to reduce these symptoms.

Clinical Trials

Several clinical trials have been conducted to assess the efficacy and safety of Fevipiprant. In a Phase II clinical trial, Fevipiprant was shown to significantly reduce the symptoms of asthma in patients who were not adequately controlled by their current medications. A Phase III trial is currently underway.

Side Effects

As with any medication, Fevipiprant may cause side effects. The most common side effects reported in clinical trials include headache, nausea, and dizziness. However, these side effects were generally mild and did not lead to discontinuation of the medication.

Future Directions

If successful in clinical trials, Fevipiprant could represent a new class of drugs for the treatment of asthma. It has the potential to provide a new option for patients who are not adequately controlled by current medications.

External Links

• Novartis Official Website
• ClinicalTrials.gov: Fevipiprant

See Also

• Asthma
• Prostaglandin D2 receptor 2
• Clinical trial
• Novartis